Long-term patient-reported outcomes from monarchE: abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer

In monarchE, abemaciclib demonstrated a sustained benefit in invasive disease-free survival and a tolerable safety profile at 42-months median follow-up. With no expected disease-related symptoms, therapies in the adjuvant setting should preserve quality of life (QoL). With all patients off abemaciclib, we report updated patient-reported outcomes (PROs) for the full 2-year treatment period and follow-up.

Source: European Journal of Cancer - January 15, 2024 Category: Cancer & Oncology Authors: Sara M. Tolaney, Valentina Guarneri, Jae Hong Seo, Josefina Cruz, Miguel Henriques Abreu, Masato Takahashi, Carlos Barrios, Kristi McIntyre, Ran Wei, Maria Munoz, Belen San Antonio, Astra M. Liepa, Miguel Martin, Stephen R.D. Johnston, Pirkko-Liisa Kellok Tags: Original Research Source Type: research